Tumor-Specific Antigen Market by Category (CT9/CT10, Idiotypic, Lineage-Restricted Antigen, Mutated, Oncofetal, Oncoviral, Overexpressed/Accumulated, and Others); By Source (Coding Region, and Non-Coding Region); By Application (Clinical and Basic Research, Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Therapeutics); By Geography (North America, Asia-Pacific, Europe, South America, and RoW), Industry Trends, Estimation & Forecast, 2018 – 2026

pa_user-types

Check Today's Best Price

$3500 Buy Now
The Global Tumor-Specific Antigen market is expected to reach $XX.X million by 2026, with a projected CAGR of XX.X% during the forecast period.
  • Market Overview

    The Global Tumor-Specific Antigen market is expected to reach $XX.X million by 2026, with a projected CAGR of XX.X% during the forecast period. Tumor-specific antigens can aid the body to make an immune response against cancer cells. They may be used as possible targets for targeted therapy or for immunotherapy to help improve the body’s immune system to kill more cancer cells. Tumor-specific antigens may also be used in laboratory tests to help identify some types of cancer.

    Market Dynamics

    Growing incidence of cancer all over the globe, surging demand for potential cancer biomarker candidates, and increasing investments in cancer diagnosis and research are the major factors driving the growth of the global tumor-specific antigen market. In addition, a rising focus on the development of targeted therapies and developments in antigen-specific T-cell therapy for cancer also propels the global market. Moreover, the advent of advanced technologies in cancer immunotherapy and regulatory approval of new monoclonal antibodies is likely to gain significant impetus for the tumor-specific antigen market share in the forthcoming years.

    Market Segmentation

    The study provides a crucial view of the tumor-specific antigen by segmenting the market based on the category, source, application, and geography. The category segment includes CT9/CT10, idiotypic, lineage-restricted antigen, mutated, oncofetal, oncoviral, overexpressed/accumulated, and others. Coding region, and non-coding region are the classification of the source segment. On the basis of application, the segment can be bifurcated into clinical and basic research, diagnostics, drug discovery and development, prognostics, risk assessment, and therapeutics. Furthermore, geographical coverage has been offered for each of the major regions including North America, Asia-Pacific, Europe, Row, and South America.

    Scope of the Global Tumor-Specific Antigen Market

    By Category

    • CT9/CT10
    • Idiotypic
    • Lineage-Restricted Antigen
    • Mutated
    • Oncofetal
    • Oncoviral
    • Overexpressed/Accumulated
    • Others

    By Source

    • Coding Region
    • Non-Coding Region

    By Application

    • Prognostics
    • Therapeutics
    • Risk Assessment
    • Drug Discovery and Development
    • Diagnostics
    • Clinical and Basic Research

    By Geography

    • North America
      • The U.S.
      • Canada
      • Mexico
    • Europe
      • UK
      • France
      • Germany
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Korea
      • Rest of APAC
    • South America
      • Brazil
      • Rest of South America
    • Rest of the World
      • Middle East
      • Africa
    keyboard_arrow_up
  • TABLE OF CONTENTS

    Chapter 1 Introduction
    1.1 Executive Summary
    1.2 Market Definition
    1.3 Market Scope

    Chapter 2 Research Methodology
    2.1 Primary Research
    2.2 Research Methodology
    2.3 Assumptions & Exclusions
    2.4 Secondary Data Sources

    Chapter 3 Market Overview
    3.1 Report Segmentation & Scope
    3.2 Key Market Trends
    3.2.1 Drivers
    3.2.2 Restraints
    3.2.3 Opportunities
    3.3 Porter’s Five Forces Analysis
    3.4 Market Share Analysis

    Chapter 4 Global Tumor-Specific Antigen Market by Category: Market Size and Forecast, 2018 – 2026
    4.1 Introduction
    4.1.1 Market Size and Forecast
    4.2 CT9/CT10
    4.2.1 Market Size and Forecast
    4.3 Idiotypic
    4.3.1 Market Size and Forecast
    4.4 Lineage-Restricted Antigen
    4.4.1 Market Size and Forecast
    4.5 Mutated
    4.5.1 Market Size and Forecast
    4.6 Oncofetal
    4.6.1 Market Size and Forecast
    4.7 Oncoviral
    4.7.1 Market Size and Forecast
    4.8 Overexpressed/Accumulated
    4.8.1 Market Size and Forecast
    4.9 Others
    4.9.1 Market Size and Forecast

    Chapter 5 Global Tumor-Specific Antigen Market by Source: Market Size and Forecast, 2018 – 2026
    5.1 Introduction
    5.1.1 Market Size and Forecast
    5.2 Coding Region
    5.2.1 Market Size and Forecast
    5.3 Non-Coding Region
    5.3.1 Market Size and Forecast

    Chapter 6 Global Tumor-Specific Antigen Market by Application: Market Size and Forecast, 2018 – 2026
    6.1 Introduction
    6.1.1 Market Size and Forecast
    6.2 Clinical and Basic Research
    6.2.1 Market Size and Forecast
    6.3 Diagnostics
    6.3.1 Market Size and Forecast
    6.4 Drug Discovery and Development
    6.4.1 Market Size and Forecast
    6.5 Prognostics
    6.5.1 Market Size and Forecast
    6.6 Risk Assessment
    6.6.1 Market Size and Forecast
    6.7 Therapeutics
    6.7.1 Market Size and Forecast

    Chapter 7 Global Tumor-Specific Antigen Market by Geography: Market Size and Forecast, 2018 – 2026
    7.1 Introduction
    7.1.1 Market Size and Forecast
    7.2 North America
    7.2.1 North America Market Size & Forecast, By Country
    7.2.2 North America Market Size & Forecast, By Category
    7.2.3 North America Market Size & Forecast, By Source
    7.2.4 North America Market Size & Forecast, By Application
    7.2.5 The U.S.
    7.2.5.1 Market Size and Forecast
    7.2.6 Canada
    7.2.6.1 Market Size and Forecast
    7.2.7 Mexico
    7.2.7.1 Market Size and Forecast
    7.3 Europe
    7.3.1 Europe Market Size and Forecast, By Country
    7.3.2 Europe Market Size and Forecast, By Category
    7.3.3 Europe Market Size and Forecast, By Source
    7.3.4 Europe Market Size & Forecast, By Application
    7.3.5 UK
    7.3.5.1 Market Size and Forecast
    7.3.6 Germany
    7.3.6.1 Market Size and Forecast
    7.3.7 France
    7.3.7.1 Market Size and Forecast
    7.3.8 Italy
    7.3.8.1 Market Size and Forecast
    7.3.9 Spain
    7.3.9.1 Market Size and Forecast
    7.3.10 Rest of Europe
    7.3.10.1 Market Size and Forecast
    7.4 Asia-Pacific
    7.4.1 Asia-Pacific Market Size and Forecast, By Country
    7.4.2 Asia-Pacific Market Size and Forecast, By Category
    7.4.3 Asia-Pacific Market Size and Forecast, By Source
    7.4.4 Asia-Pacific Market Size and Forecast, By Application
    7.4.5 India
    7.4.5.1 Market Size and Forecast
    7.4.6 China
    7.4.6.1 Market Size and Forecast
    7.4.7 Australia
    7.4.7.1 Market Size and Forecast
    7.4.8 Japan
    7.4.8.1 Market Size and Forecast
    7.4.9 South Korea
    7.4.9.1 Market Size and Forecast
    7.4.10 Rest of Asia-Pacific
    7.4.10.1 Market Size and Forecast
    7.5 South America
    7.5.1 South America Market Size and Forecast, By Country
    7.5.2 South America Market Size and Forecast, By Category
    7.5.3 South America Market Size and Forecast, By Source
    7.5.4 South America Market Size and Forecast, By Application
    7.5.5 Brazil
    7.5.5.1 Market Size and Forecast
    7.5.6 Rest of South America
    7.5.6.1 Market Size and Forecast
    7.6 RoW
    7.6.1 RoW Market Size and Forecast, By Country
    7.6.2 RoW Market Size and Forecast, By Category
    7.6.3 RoW Market Size and Forecast, By Source
    7.6.4 RoW Market Size and Forecast, By Application
    7.6.5 Middle East
    7.6.5.1 Market Size and Forecast
    7.6.6 Africa
    7.6.6.1 Market Size and Forecast

    Chapter 8 Company Profiles
    8.1 Abcam Plc
    8.2 Agilent Technologies Inc.
    8.3 Bio-Rad Laboratories Inc.
    8.4 Biomrieux Sa
    8.5 Caris Life Sciences Inc.
    8.6 Creative Diagnostics
    8.7 Eli Lilly and Co.
    8.8 Enzo Biochem Inc.
    8.9 F. Hoffmann-La Roche Ltd.
    8.10 Janssen Global Services Llc
    8.11 Go Therapeutics
    8.12 Lee Biosolutions Inc.
    8.13 Merck Millipore
    8.14 Perkinelmer Inc.
    8.15 Quest Diagnostics
    8.16 Signosis Inc.

    keyboard_arrow_up
  • Tumor-Specific Antigen Market Key Players

    • Abcam Plc
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Biomrieux Sa
    • Caris Life Sciences Inc.
    • Creative Diagnostics
    • Eli Lilly and Co.
    • Enzo Biochem Inc.
    • Hoffmann-La Roche Ltd.
    • Janssen Global Services Llc
    • Go Therapeutics
    • Lee Biosolutions Inc.
    • Merck Millipore
    • Perkinelmer Inc.
    • Quest Diagnostics
    • Signosis Inc.
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS

SHARE YOUR CART